Tianzhihang
Latest news, March 2, domestic "surgical robots, the first stock" Tianzhihang formally disclosed the "to the specific object of the issue of A-share issuance of report," the results of the fixed-price increase formally came out. It is understood that the funds raised will be used for the "new generation of orthopedic surgical robot research and development and industrialization project" and "intelligent medical center construction project" construction. As of September 2022, Tianzhihang's orthopedic surgical robot products have been clinically applied in more than 150 medical institutions in China, with a total of more than 30,000 surgeries completed. Previously, Tianzhihang announced 2022 results, is expected to achieve operating income of 150 million yuan - 170 million yuan in 2022, net profit loss of 100 million yuan to a loss of 120 million yuan.
Microtron Robotics
In March, Microtron Robotics Hong Kong Stock Exchange announced that 2022 revenue growth of more than 850% year-on-year, the annual net loss is expected to be about 1.1 billion yuan - 1.15 billion yuan. It is understood that China's domestic surgical robot Microtronics Tumai four-arm laparoscopic surgical robot in 2022 was approved by the NMPA to market, becoming the first certified four-arm laparoscopic surgical robot, and gradually open the era of domestic self-researching laparoscopic robot clinical popularization.
Casting Robotics
Casting Robotics has developed a number of original surgical robotic systems for clinical applications, and created a series of digital, intelligent and minimally invasive orthopedic solutions. The company has set up a sub-center of the Ministry of Education's Engineering Research Center for Precision Bone and Joint Medicine and a medical orthopedic robotics lab. 2022, the Zohang 300 developed by Casting Robotics has been approved by the NMPA Class III certificate.
Stryker
Recently, Stryker announced that the Mako surgical robot has entered the 2.0 stage.
To date, the global installed base of Mako surgical robots is around 1,500 units, and the total number of surgeries performed worldwide has exceeded one million. Meanwhile, it has been widely used in Chinese clinics, with the volume of surgeries boosted from 3,000 units in August 2021 to successfully exceed 6,000 units by the end of September 2022.
Medtronic
Recently, Medtronic has made a personnel change, and Mike Marinaro, who was appointed president of Surgical Robotics Operations in March 2022, has now become executive vice president and president of Medtronic's Surgical Operations. Some people believe that Medtronic's surgical robots may be combined with the Surgical Innovation division. 2021, Medtronic MAZOR X spinal surgery intelligent navigation robot was officially approved in April in China. Previously, the MAZOR series of products has 18 years of clinical application experience in foreign countries, and a total of more than 50,000 successful surgeries.
Jiemai Bangmei
It is understood that in March 2020, Medtech, a subsidiary of Jiemai Bangmei, developed and produced the surgical robot ROSA One, which passed the NMPA audit and officially landed in the Chinese market, and it became the only one approved and listed on the market, which can be applied to both brain and spine surgery navigation robot, and it formally started the layout of its market in China. The NMPA is the only robot approved for use in both brain surgery and spine surgery in China.
For more information, please refer to the "China Medical Devices Blue Book (2022 Edition)" published by Eshare's public website
.